[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366199-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366199-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","altered-glycosylation-of-evs-in-cancers-galectin-3-binding-protein-lgals3bp","Altered glycosylation of EVs in cancers - galectin 3-binding protein (LGALS3BP)","","Extracellular vesicles (EVs) are membrane-bound carriers secreted by many cell types and present in biofluids, supporting their use in disease biomarker discovery. Glycans within EVs undergo glycosylation, a key post-translational modification linked to biological regulation. Aberrant EV glycosylation is strongly associated with cancer. This review analyzes how EV glycosylation patterns change in cancer, highlighting N-glycan dysregulation, increased terminal sialic acid, and LGALS3BP as a recurrent altered glycosylated protein pattern with diagnostic and prognostic potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/altered-glycosylation-of-evs-in-cancers-galectin-3-binding-protein-lgals3bp/366199/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/altered-glycosylation-of-evs-in-cancers-galectin-3-binding-protein-lgals3bp/366199.png","ImageObject",300,407,{"name":42,"@type":43},"Terk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this review?","Question",{"text":63,"@type":64},"The review examines alterations in EV glycosylation patterns in cancer and explains their biological implications, with emphasis on diagnostic and prognostic applications.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are extracellular vesicles (EVs) relevant to cancer detection?",{"text":68,"@type":64},"EVs are present in biofluids and carry complex cargos, including glycans, enabling detection of disease-associated molecular patterns for circulating cancer identification.",{"name":70,"@type":61,"acceptedAnswer":71},"Which glycosylation changes and marker are highlighted as key findings?",{"text":72,"@type":64},"Key findings include elevated terminal sialic acid levels, dysregulated N-glycan patterns, and enrichment of the galectin-3 binding protein (LGALS3BP) across multiple cancer types.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366199,1790504063,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Koh Kok et al. Discover Oncology (2025) 16:1336 [https://doi.org/10.1007/s12672-025-03121-x](https://doi.org/10.1007/s12672-025-03121-x)  \nDiscover Oncology  \nREVIEW Open Access  \nAltered glycosylation of EVs in cancers: galectin 3-binding protein (LGALS3BP)  \nJie-Yi Koh Kok 1, Bey-Hing Goh2,3,4 and Wai-Leng Lee 1*  \n*Correspondence:  \nWai-Leng Lee [lee.wai.leng@monash.edu](lee.wai.leng@monash.edu)[ ](lee.wai.leng@monash.edu)1School of Science, Monash University Malaysia,  \n47500 Subang Jaya, Malaysia 2Sunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, Sunway University, Sunway City, Selangor, Malaysia  \n3Biofunctional Molecule Exploratory (BMEX) Research Group, School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor Darul Ehsan, Malaysia  \n4Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, 235 Jones St, Ultimo NSW 2007, Sydney, Australia  \nAbstract  \nIntroduction Extracellular vesicles (EVs) are membrane-bound structures secreted by various cell types, acting as carriers of complex cargos that facilitate intercellular communication. Their presence in biofluids highlights their potential for disease biomarker identification. Glycans, crucial components of EVs, undergo glycosylation, a key post-translational modification (PTM) involved in many biological processes. Aberrant glycosylation is linked to disease, particularly cancer.  \nAreas covered This review examines alterations in EV glycosylation patterns in cancer and their biological implications. It synthesizes findings from cell studies and biofluid analyses (including blood and urine), emphasizing the potential of combined glycosylation profiles as circulating cancer detection. Key findings highlight the elevation of terminal sialic acid levels, dysregulation of N-glycan patterns, and the identification of galectin-3-binding protein (LGALS3BP) as a common pattern of altered glycosylated protein in cancer-derived EVs.  \nExpert opinion/commentary This review uniquely suggests a novel combination of the altered glycosylation pattern of cancer-derived EVs based on changes observed in current studies. By highlighting specific alterations that differentiate cancer-derived EVs from those of healthy origin, the analysis offers valuable insights into diagnostic and prognostic applications. These findings may facilitate the development of non-invasive biomarkers that enhance early cancer detection and monitoring.  \nHighlights  \n• Cancer transformation often disrupts glycosylation pathways, positioning EVglycosylation as a potential source of cancer biomarkers.  \n• Surface glycoconjugates play essential roles in protein sorting, EV biogenesis, and cancer progression, with distinct glycosylation changes distinguishing normal from cancer-derived EVs.  \n• Galectin-3 binding protein (LGALS3BP) is highly enriched in cancer-derived EVs, with substantial elevation observed across up to seven different cancer types.  \n• The dysregulated glycosylation pattern, involving LGALS3BP, N-glycan, and sialicacid, may drive glycoprotein alterations, contributing to cancer progression.  \nKeywords Extracellular vesicles, Biomarkers, Glycosylation, Cancer, Galectin-3 binding protein (LGALS3BP)  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless ind","cbCaiaAC8STQUV82","https://ap.wps.com/l/cbCaiaAC8STQUV82","pdf",1348118,"English","# Abstract\n# Introduction\n# Areas covered\n# Key findings\n# Expert opinion/commentary\n# Highlights\n# Keywords\n# Graphical abstract","[{\"question\":\"What is the main focus of this review?\",\"answer\":\"The review examines alterations in EV glycosylation patterns in cancer and explains their biological implications, with emphasis on diagnostic and prognostic applications.\"},{\"question\":\"Why are extracellular vesicles (EVs) relevant to cancer detection?\",\"answer\":\"EVs are present in biofluids and carry complex cargos, including glycans, enabling detection of disease-associated molecular patterns for circulating cancer identification.\"},{\"question\":\"Which glycosylation changes and marker are highlighted as key findings?\",\"answer\":\"Key findings include elevated terminal sialic acid levels, dysregulated N-glycan patterns, and enrichment of the galectin-3 binding protein (LGALS3BP) across multiple cancer types.\"}]","Altered glycosylation of EVs in cancers - galectin 3-binding protein (LGALS3BP) | PDF",1790164215,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd54bc5db3a1ecf57e0d93db1e0ebc85.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2999011162a0a469e922925e637a722.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c352a9bae70a2179f9d9e193da37a9f.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aec426cc55ee5e2d936cf96dfc5844eb.webp",980,1306]